title: Preferential prescribing of tibolone and combined estrogen plus progestogen therapy in postmenopausal women.
abstract: OBJECTIVE
  To verify whether tibolone is preferentially prescribed to women at an increased risk for endometrial and breast cancer compared with women who were prescribed combined estrogen + progestogen therapies, including sequential conjugated equine estrogens/norgestrel, sequential conjugated equine estrogens/medroxyprogesterone acetate, continuous conjugated equine estrogens/medroxyprogesterone acetate, or continuous 17beta-estradiol/norethisterone acetate.
  
  
  METHODS
  This was a descriptive study using the General Practice Research Database, a UK primary care database. A total of 16,746 women who, between July 1, 1999, and June 30, 2001, were prescribed either tibolone or one of the estrogen + progestogen regimens listed above were included. The main outcome measures were risk factors associated with endometrial cancer and breast cancer.
  
  
  RESULTS
  The clinical background of women who were prescribed tibolone differed from that of women who were prescribed combination products. More frequently than expected, women who were most recently prescribed tibolone had a history of chronic breast disease, a personal history of breast cancer, or a history of (long-term) estrogen-only therapy. Furthermore, medical records of this group of women showed more frequent reports of hypertension and previous uterine procedures.
  
  
  CONCLUSIONS
  This study confirms previous findings that in the United Kingdom, general practitioners seem to prescribe tibolone preferentially to women with increased risks of breast and endometrial cancer as compared with women who are prescribed estrogen + progestogen products.
authors.affiliation: NV Organon, Oss, The Netherlands. erica.velthuis@organon.com
authors.forename: Erica J M
authors.initials: EJ
authors.lastname: Velthuis-Te Wierik
authors.forename: Paul T
authors.initials: PT
authors.lastname: Hendricks
authors.forename: Carlos
authors.initials: C
authors.lastname: Martinez
mesh_terms: D001943:Breast Neoplasms / Q000517:prevention & control; D016889:Endometrial Neoplasms / Q000517:prevention & control; D004958:Estradiol / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy / Q000379:methods; D005194:Family Practice / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D008487:Medical History Taking / Q000706:statistics & numerical data; D020380:Needs Assessment / Q000706:statistics & numerical data; D009652:Norpregnenes / Q000627:therapeutic use*; D017698:Postmenopause; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011369:Professional-Patient Relations; D011372:Progestins / Q000627:therapeutic use; D006113:United Kingdom; D016387:Women's Health
chemical_list: D009652:Norpregnenes; D011372:Progestins; D004958:Estradiol; C027385:tibolone